Анализ уровня безопасности фармакотерапии хронических заболеваний психической группы: региональный аспект

Н. В. Иванова, В. С. Белов, Т. В. Кузьмина УО «Псковский государственный университет», ГКУЗ Псковской области «Управление фармации»

2021 №2 | Оригинальные научные публикации

Аннотация

Список литературы

Скачать полнотекстовую статью

В статье изложены вопросы оценки уровня безопасности фармакотерапии хронических заболеваний психической группы в условиях отдельно взятого субъекта Российской Федерации. Выявлено, что в Псковской области при финансировании из федерального и регионального бюджетов льготного лекарственного обеспечения заболеваний психической группы самыми высоко затратными являются эпилепсии и шизофрении. Выполнены частотный анализ встречаемости побочных эффектов при приеме психотропных препаратов и их систематизация по типу А – предсказуемые и типу В – непредсказуемые реакции. Установлены, что побочные реакции чаще всего встречаются при применении противосудорожных препаратов.

Ключевые слова:

психические болезни, психофармакотерапия, нежелательные побочные реакции, безопасность фармакотерапии

Analysis of the safety level of pharmacotherapy chronic diseases of the mental group: regional aspect

The article presents the issues of assessing the level of safety of pharmacotherapy of chronic diseases of the mental group in a single subject of the Russian Federation. It was found that in the Pskov region, when subsidized drug provision for mental illness is financed from the Federal and regional budgets, epilepsies and schizophrenia are the most expensive. The frequency analysis of the occurrence of side effects when taking psychotropic drugs and their systematization by type A – predictable and type B – unpredictable reactions were performed. It is established that adverse reactions are most often encountered when using anticonvulsants.

Keywords

mental illness, psychopharmacotherapy, unwanted side reactions, safety of pharmacotherapy

1. Astakhova, A. V., Lepakhin V. K. Lecarstva: Neblsgopriiytnye pobochnye reakcii i control bezopasnosti, – M.: Eksmo, 2008. – 256 p.
2. Belousov, Yu. B., Kukes V. G., Lepakhin V. K., Petrov V. I. Clinicheskaya pharmacologiya. Nationalnoe rukovodstvo. – M.: GEOTARMedia, 2014. – 976 p.
3. Davydov, A. T. Osnovnye principy lecheniya psyhicheskih rastroystv (rol i psihi mesto psihopharmacoterapii) // Obzory po clinicheskoy pharmacologii. – 2004. – Т. 23, № 2. – P. 52–61.
4. Feoktistova, Yu. V., Poddubny E. A., Maneeva E. S., Eliseeva E. V. Legislative and organizational fundamentals of preferential medicinal provision of certain categories of citizens // Tavricheskiy medicobiologucheskiy vtstnik. – 2018. – Т. 21, № 4. – P. 120–127.
5. Gurovich, I., Lubov E. Pharmacoepidemiolodiya i pharmacoetconomika v psyhiatrii. – M.: MedpractikaV, 2003. – 264 p.
6. Hasan, A., Falkai P., Vobrok T., Liberman D., Glentoy B., Gattaz V. F., Meller H. Yu., Mosolov S. N. i dr. Rukovodstvo po biologicheskoy terapii schizophrenii Vsemirnoy federacii obshchestv biologicheskoy psyhiatrii (WFSBP) // Sovremennaya terapiya psyhicheskih rastroystv. Tematicheskiy vypusk. – 2014. – № 2. – 36 с.
7. Ivanova, N. V. Regionalnye osobennocti monitoringa bezopasnosty lekastvennyh sredstv v Pskovskoy oblasty // Trudy 10 vserossiyskoy nauchnopracticheskoy conferencii s mejdunarodnym uchastiem «Zdorovie – osnova chelovecheskogo potenciala.Problemy i puty ih resheniya». – SPb., 2015. – T. 10, ch. 1. – P. 425–427.
8. Kachaeva, M. A., Shport S. V., Trushchelev S. A. WHO strategic directions for the protection of mental health //Rossiyskiy psyhiatricheskiy journal. – 2017. – № 6. – P. 10–23.
9. Kochetov, A. G., Lyang O. V., Masenko V. P., Zhirov I. V., Nakonechnikov S. N., Tereshchenko S. N. Metody statisticheskoy obrabotky medicinskih dannyh: Metodicheskie recomendacii dlya ordinatorov i aspirantov medicinskih uchebnyh zavedeniy, nauchnyh rabotnikov. – M.: RKNPK, 2012. – 42 p.
10. Krot, K. V., Meshalkina S. Yu., Slobodenuk E. V. Socialno economicheskaiy znachimost psyhicheskih rastroystv: regionalnye aspecty // Dalnevostochniy medicinckiy journal. – 2016. – № 1. – P. 91–96.
11. Probyn, A. J. Some drugs more equal than others: pseudogenerics and commercial practice // Aust. Health Rev. – 2004. – Vol. 28, № 2. – P. 207–217. DOI: 10.1071/AH040207 ИНОСТР.
12. Shmatova, Yu. E. Dynamics of statistical and sociological indicators of mental health of the Russian Population. Problems of Territory’s Development. – 2019. – № 3 (101). – P. 76–96. DOI: 10.15838/ptd.2019.3.101.5.
13. Smirnova, I. (2020) Invalidnost po psyhicheskomu zabolevaniyu (electronic resource). Available at: https://invalidu.com/bolezny/invalidnostpsihicheskomuzabolevaniyu (accessed 20 July 2020).
14. Versantvoort, C., Maliepaard M., Lekkerkerker F. Generics: what is the role of registration authorities // Medicine. The Netherlands journal of medicine. – 2008. – Vol. 66, № 2. – P. 62–66. ИНОСТР.
15. Vorobiev, P. A. ABC, VEN i chastotniy analizy v sdravoohranenii // Problemy standartizacii v sdravoohranenii. – 2004. – № 3. – P. 3–5. References
1. Astakhova, A. V., Lepakhin V. K. Medication: Adverse Reactions and Safety Controls. – M.: Eksmo, 2008. – 256 p.
2. Belousov, Yu. B., Kukes V. G., Lepakhin V. K., Petrov V. I. Clinical Pharmacology. National guidance. – M.: GEOTARMedia, 2014. – 976 p.
3. Davydov, A. T. Basic principles of treatment of mental disorders (role and psyche place of psychopharmacotherapy) // Obzory po clinicheskoy pharmacologii. – 2004. – T. 23, № 2. – P. 52–61.
4. Feoktistova, Yu. V., Poddubny E. A., Maneeva E. S., Eliseeva E. V. Legislative and organizational fundamentals of preferential medicinal provision of certain categories of citizens // Tavricheskiy medicobiologucheskiy vtstnik. – 2018. – T. 21, № 4. – P. 120–127.
5. Gurovich, I., Lubov E. Pharmacoepidemiolodymy and pharmacoetsonomics in psychiatry. – M.: MedpractikaV, 2003. – 264 p.
6. Hasan, A., Falkai P., Vobrok T., Liberman D., Glentoy B., Gattaz V. F., Meller H. Yu., Mosolov S. N. i dr. Biological Therapy Guide for Schizophrenia of the World Federation of Biological Psychiatric Societies (WFSBP) // Sovremennaya terapiya psyhicheskih rastroystv. Tematicheskiy vypusk. – 2014. – № 2. – 36 s.
7. Ivanova, N. V. Regional features of drug safety monitoring in the Pskov region // Trudy 10 vserossiyskoy nauchnopracticheskoy conferencii s mejdunarodnym uchastiem «Zdorovie – osnova chelovecheskogo potenciala.Problemy i puty ih resheniya». – SPb., 2015. – T. 10, ch. 1. – P. 425–427.
8. Kachaeva, M. A., Shport S. V., Trushchelev S. A. WHO strategic directions for the protection of mental health //Rossiyskiy psyhiatricheskiy journal. – 2017. – № 6. – P. 10–23.
9. Kochetov, A. G., Lyang O. V., Masenko V. P., Zhirov I. V., Nakonechnikov S. N., Tereshchenko S. N. Methods of statistical processing of medical data: Methodological recommendations for residents and graduate students of medical educational institutions, researchers. – M.: RKNPK, 2012. 42 p.
10. Krot, K. V., Meshalkina S. Yu., Slobodenuk E. V. Socioeconomic significance of mental disorders: regional aspects // Dalnevostochniy medicinckiy journal. – 2016. – № 1. – P. 91–96.
11. Probyn, A. J. Some drugs more equal than others: pseudogenerics and commercial practice // Aust. Health Rev. – 2004. – Vol. 28, № 2. – P. 207–217. DOI: 10.1071/AH040207 INOSTR
12. Shmatova, Yu. E. Dynamics of statistical and sociological indicators of mental health of the Russian Population. Problems of Territory’s Development. – 2019. – № 3 (101). – P. 76–96. DOI: 10.15838/ptd.2019.3.101.5.
13. Smirnova, I. (2020) Mental Disability [Electronic resource]. Available at: https://invalidu.com/bolezny/invalidnostpsihicheskomuzabolevaniyu (accessed 20 July 2020).
14. Versantvoort, C., Maliepaard M., Lekkerkerker F. Generics: what is the role of registration authorities // Medicine. The Netherlands journal of medicine. – 2008. – Vol. 66, № 2. – P. 62–66. INOSTR
15. Vorobiev, P. A. ABC, VEN and frequency analyzes in health care // Problemy standartizacii v sdravoohranenii. – 2004. – № 3. – P. 3–5.